Lisata Therapeutics
LSTA
33 hedge funds and large institutions have $13.6M invested in Lisata Therapeutics in 2013 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 12 increasing their positions, 7 reducing their positions, and 8 closing their positions.
71% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 7
25% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 8
13% more capital invested
Capital invested by funds: $12M → $13.6M (+$1.61M)
6% more funds holding
Funds holding: 31 → 33 (+2)
82% less call options, than puts
Call options by funds: $98K | Put options by funds: $557K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PRCM
Pine River Capital Management
Minnetonka,
Minnesota
|
+$2.51M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$983K |
| 3 |
SC
Sophrosyne Capital
New York
|
+$462K |
| 4 |
US Bancorp
Minneapolis,
Minnesota
|
+$329K |
| 5 |
California Public Employees Retirement System
Sacramento,
California
|
+$198K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$672K |
| 2 |
Morgan Stanley
New York
|
-$384K |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$322K |
| 4 |
Renaissance Technologies
New York
|
-$257K |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$105K |
LSTA Hedge Fund Activity: Q4 2013 in Review
33 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Lisata Therapeutics (LSTA) for Q4 2013, worth a combined $13.6M — up 13% from $12M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new LSTA positions and 8 closed out — a net gain of 2 holders — while 12 added to existing stakes and 7 trimmed.
The largest buyer was Pine River Capital Management, opening a new position worth an estimated $2.51M. The largest seller was Perceptive Advisors, cutting an estimated $672K.
- 33 institutional investors held Lisata Therapeutics (LSTA) as of Q4 2013, up from 31 in Q3 2013.
- Funds reported $13.6M of Lisata Therapeutics stock for Q4 2013, up 13% quarter-over-quarter.
- 10 funds opened new Lisata Therapeutics positions in Q4 2013 and 8 closed out, a net change of +2 holders.
- The largest Lisata Therapeutics buyer in Q4 2013 was Pine River Capital Management, an estimated $2.51M added.
- The largest Lisata Therapeutics seller in Q4 2013 was Perceptive Advisors, an estimated $672K sold.
Based on aggregated 13F filings for Q4 2013.